At the news
? NEUTRALIMPACT 4/10 8-K filed Feb 26, 2026 at 08:22 ET
Kymera Therapeutics entered into a $500 million at-the-market (ATM) equity offering agreement with TD Securities (USA) LLC, terminated its prior ATM agreement with Jefferies LLC, and filed a resale prospectus supplement for up to 31.4 million shares held by certain selling stockholders. The ATM program allows Kymera to raise capital opportunistically, while the resale filing enables passive selling by existing investors without Kymera receiving proceeds.
- Entered into a $500 million at-the-market (ATM) equity offering agreement with TD Securities (USA) LLC.
- Terminated the prior Open Market Sale Agreement with Jefferies LLC.
- Filed a resale prospectus supplement for up to 18.8 million common shares and 12.6 million warrant shares held by selling stockholders.
- The ATM program allows Kymera to sell shares from time to time at its discretion, with TD Securities acting as sales agent for a commission of up to 3.0%.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access